MRI helps diagnose prostate cancer more accurately
In a world first, an Australian clinical trial has shown that biopsy guided by MRI can significantly improve the diagnosis of life-threatening prostate cancer and reduce the over-diagnosis of non-life-threatening cases, thus avoiding the side effects of unnecessary treatment.
Predicting prostate cancer survival by measuring circulating tumor cells
New research by USC Norris Comprehensive Cancer Center scientists demonstrates that measuring circulating tumor cells (CTCs) - the cells that spread cancer through the body - may be a better predictor of patient survival than the prostate specific antigen (PSA).The research was published in the Journal of Clinical Oncology by a team led by Amir Goldkorn, M.D.
Most men with early prostate cancer do not benefit from primary androgen deprivation therapy
A study of more than 15,000 men with early stage prostate cancer finds that those who received androgen deprivation as their primary treatment instead of surgery or radiation did not live any longer than those who received no treatment.
Discovery of gene family that suppress prostate cancer
Cornell researchers report they have discovered direct genetic evidence that a family of genes, called MicroRNA-34 (miR-34), are bona fide tumor suppressors.The study is published in the journal Cell Reports.Previous research at Cornell and elsewhere has shown that another gene, called p53, acts to positively regulate miR-34. Mutations of p53 have been implicated in half of all cancers.
Risk of prostate cancer death decreased by PSA-testing and early treatment
Mortality in prostate cancer is lower in areas with frequent use of PSA testing compared with areas with little testing shows a study published online in Journal of the National Cancer Institute by researchers from Umeå University, Sweden and Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Convenient, less expensive, but possibly riskier new prostate cancer treatment: SBRT
A faster and less expensive form of radiotherapy for treating prostate cancer may come at a price, according to a new study by Yale School of Medicine researchers - a higher rate of urinary complications.The standard external beam radiation therapy for prostate cancer is called intensity modulated radiation therapy (IMRT).
Prostate cancer outcomes predicted by bone turnover markers: findings could influence treatment and clinical trial design
Biomarkers for bone formation and resorption predict outcomes for men with castration-resistant prostate cancer, a team of researchers from UC Davis and their collaborators have found. Their study, published online in the Journal of the National Cancer Institute, also found that the markers identified a small group of patients who responded to the investigational drug atrasentan.
Target identified for shutting down growth of prostate cancer cells
Scientists at UT Southwestern Medical Center have identified an important step toward potentially shutting down the growth of prostate cancer cells.Dr. Ralf Kittler, Assistant Professor of Pharmacology, studies ERG, a protein that facilitates the transformation of normal prostate cells into cancer cells.
Surgery better than watchful waiting for younger prostate cancer patients
A new study in the New England Journal of Medicine finds that mortality rates are lower for younger men having surgery for prostate cancer, compared with those who follow watchful waiting.Prostate cancer is common among older men and rare in men under the age of 40.
New diagnostic, treatment approach for aggressive prostate cancer suggested by cholesterol-metabolism study
Researchers have discovered a link between prostate cancer aggressiveness and the accumulation of a compound produced when cholesterol is metabolized in cells, findings that could bring new diagnostic and treatment methods.Findings also suggest that a class of drugs previously developed to treat atherosclerosis might be repurposed for treatment of advanced prostate cancer.